Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2011, vol. 20, nr 2, March-April, p. 165–175

Publication type: original article

Language: English

Metabolic Abnormalities in Siblings of Women with Polycystic Ovary Syndrome

Zaburzenia metaboliczne u rodzeństwa kobiet z zespołem wielotorbielowatych jajników

Agnieszka Lenarcik1,, Bożena Bidzińska-Speichert1,, Urszula Tworowska-Bardzińska1,

1 Department of Endocrinology, Diabetology and Isotope Treatment, Wroclaw Medical University, Poland

Abstract

Background. There is evidence of familial occurrence of metabolic disturbances in first-degree relatives of women with Polycystic Ovary Syndrome (PCOS).
Objectives. The aim of this study was to establish whether siblings of women with PCOS have the metabolic abnormalities that are typical of PCOS.
Material and Methods. Forty-four sisters and forty-two brothers of women with PCOS were recruited. There were two control groups consisting of 70 healthy women and 30 healthy men. Anthropometric and metabolic parameters (glucose and insulin, fasting and during an oral glucose tolerance test (OGTT 30’, 60’ and 120’), insulinsensitivity and insulin-resistance indexes, lipidogram) were assessed in all subjects.
Results. In comparison with the controls, siblings of women with PCOS had higher glucose levels, higher insulin levels at 120’ and higher mean insulin levels during the OGTT. There were no differences in the insulin-sensitivity indexes or insulin resistance indexes between siblings and the controls. The total cholesterol and LDL-cholesterol levels were higher in sisters and brothers of women with PCOS than in the controls.
Conclusion. Siblings of patients with PCOS are predisposed to some metabolic abnormalities, such as higher fasting glycemia, glucose intolerance and a more adverse lipid profile than the controls. Insulin resistance in PCOS families is related mainly to obesity and seems not to have a genetic background.

Streszczenie

Wprowadzenie. Istnieją dane na temat rodzinnego występowania zaburzeń metabolicznych u krewnych pierwszego stopnia kobiet z zespołem wielotorbielowatych jajników (PCOS).
Cel pracy. Ocena rodzeństwa kobiet z PCOS pod kątem występowania zaburzeń metabolicznych.
Materiał i metody. Zbadano 44 siostry i 42 braci pacjentek z PCOS. Grupy kontrolne stanowiło 70 zdrowych kobiet i 30 zdrowych mężczyzn. U wszystkich zrekrutowanych oceniono wskaźniki antropometryczne i metaboliczne (stężenia glukozy i insuliny na czczo oraz podczas doustnego testu obciążenia glukozą – OGTT – 30’, 60’ i 120’, wskaźniki insulinowrażliwości i insulinooporności oraz pełny lipidogram).
Wyniki. Rodzeństwo kobiet z PCOS w porównaniu z odpowiednimi grupami kontrolnymi miało większe stężenia glukozy podczas OGTT oraz stężenia insuliny w 120’ i średnie stężenia insuliny podczas OGTT. Nie było różnic dotyczących wartości wskaźników insulinowrażliwości i insulinooporności między rodzeństwem pacjentek z PCOS a odpowiednimi grupami kontrolnymi. Siostry i bracia charakteryzowali się większymi stężeniami cholesterolu całkowitego i cholesterolu LDL niż osoby z grup kontrolnych.
Wnioski. Rodzeństwo pacjentek z PCOS jest predysponowane do występowania zaburzeń metabolicznych, takich jak: nieprawidłowa tolerancja glukozy, większe stężenia glukozy na czczo oraz bardziej niekorzystny profil lipidowy w porównaniu z rodzeństwem zdrowych kobiet. Insulinooporność w rodzinach pacjentek z PCOS jest związana z otyłością i wydaje się, że nie ma podłoża genetycznego.

Key words

PCOS, siblings, familial occurrence, metabolic disturbances

Słowa kluczowe

PCOS, rodzeństwo, występowanie rodzinne, zaburzenia metaboliczne

References (31)

  1. Dunaif A: Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis. Endocr Rev 1997, 18, 774–800.
  2. Carmina E, Lobo RA: Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy is Associated with Significant Morbidity in Women. J Clin Endocrinol Metab 1999, 84, 1897–1899.
  3. American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Commiitee. Endocr Pract 2005, 11, 126–134.
  4. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH: Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005, 106, 131–137.
  5. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN: PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006, 91, 48–53.
  6. Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R: Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 2001, 75, 53–58.
  7. Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A: Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Nat Acad Sci USA 1998, 95, 14956–14960.
  8. Yildiz BO, Yarali H, Oguz H, Bayraktar M: Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003, 88, 2031–2036.
  9. Legro RS, Kunselman AR, Demers L, Wang SC, Bentley-Lewis R, Dunaif A: Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87, 2134–2138.
  10. Kaushal R, Parchure N, Bano G, Kaski JC, Nussey SS: Insulin resistance and endothelial dysfunction in the brothers of Indian subcontinent Asian women with polycystic ovaries. Clin Endocrinol (Oxf) 2004, 60, 322–328.
  11. Legro RS, Bentley-Lewis R, Driscoll A, Wang S, Dunaif A: Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab 2002, 87, 2128–2133.
  12. Sam S, Legro RS, Bentley-Lewis R, Dunaif A: Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90, 4797–4802.
  13. Matthews DR, Hosker JP, Rudenski AS: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 42, 678–687.
  14. Ducan MH, Singh BM, Wise PH: A simple measure of insulin resistance. Lancet 1995, 346, 12–121.
  15. Katz A, Nambi SS, Mather K: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85, 2402–2410.
  16. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999, 22, 1462–1470.
  17. Yilmaz M, Bukan N, Ersoy R, Karakoc A, Yetkin I, Ayvaz G, Cakir N, Arslan M: Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Hum Reprod 2005, 20, 2414–2420.
  18. Unlühizarci K, Ozocak M, Tanriverdi F, Atmaca H, Kelestimur F: Investigation of hypothalamo-pituitary-gonadal axis and glucose intolerance among the first-degree female relatives of women with polycystic ovary syndrome. Fertil Steril 2007, 87, 1377–1382.
  19. Diamanti-Kandarakis E, Alexandraki K, Bergiele A, Kandarakis H, Mastorakos G, Aessopos A: Presence of metabolic risk factors in non-obese PCOS sisters: evidence of heritability of insulin resistance. J Endocrinol Invest 2004, 27, 931–936.
  20. Norman RJ, Masters S, Hague W: Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertil Steril 1996, 66, 942–947.
  21. Raskauskiene D, Jones PW, Govind A, Obhrai M, Clayton RN: Do polycystic ovaries on ultrasound scan indicate decreased insulin sensitivity in sisters of women with polycystic ovary syndrome? J Clin Endocrinol Metab 2005, 90, 2063–2067.
  22. Baillargeon J, Carpentier AC: Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects. Diabetologia 2007, 50, 2424–2432.
  23. Bidzińska B: Związek hiperandrogenizmu z otyłością, insulinoopornością, peptydami regulującymi apetyt i wydatek energetyczny oraz polimorfizmem genu receptora aktywowanego proliferatorami peroksysomów gamma 2 (PPARγ2). Rozprawa na stopień doktora habilitowanego. Akademia Medyczna, Wrocław 2004.
  24. Palmert MR, Gordon CM, Kartoshov AI, Legro RS, Emans SJ, Dunaif A: Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87, 1017–1023.
  25. Plymate SR, Matej LA, Jones RE, Friedl KE: Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988, 67, 460–464.
  26. Kurzrock R, Cohen PR: Polycystic ovary syndrome in men: Stein-Leventhal syndrome revisited. Med Hypotheses 2007, 68, 480–483.
  27. Sam S, Coviello AD, Sung YA, Legro RS, Dunaif A: Metabolic phenotype in the brothers of women with polycystic ovary syndrome. Diabetes Care 2008, 31, 1237–1241.
  28. De Oliveira EP, De Lima MD, De Souza ML: Metabolic syndrome, its phenotypes, and insulin resistance by HOMA-IR. Arq Bras Endocrinol Metabol 2007, 51, 1506–1515.
  29. Meigs JB: The metabolic syndrome. BMJ 2003, 327, 61–62.
  30. Colilla S, Cox NJ, Ehrmann DA: Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab 2001, 86, 2027–2031.
  31. Bloomgarden ZT: Second World Congress on the Insulin resistance Syndrome. Mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy. Diabetes Care 2005, 28, 1821–1830.
© Wroclaw Medical University